Macitentan: Medgend

Macitentan FDA Approved Drugs

OPSUMIT [Macitentan^{C₁₉H₂₀Br₂N₆O₄S}]

10mg (oral tablet)

Actelion Pharms Ltd^{Oct 18, 2013}

Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition.
Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition.
Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

UPTRAVI [Selexipag^{C₂₆H₃₂N₄O₄S}]

0.2mg (oral tablet)

0.4mg (oral tablet)

0.6mg (oral tablet)

0.8mg (oral tablet)

1.2mg (oral tablet)

1.4mg (oral tablet)

1.6mg (oral tablet)

1mg (oral tablet)

Actelion Pharms Ltd^{Dec 21, 2015}

Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag.
Method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag.
Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.